SpringWorks Therapeutics, Inc.

Equities

SWTX

US85205L1070

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
44.77 ^USD	-0.95%		+4.24%	+22.66%

May. 15	Transcript : SpringWorks Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 03:40 PM
May. 02	Wedbush Raises SpringWorks Therapeutics' Price Target to $75 From $70, Keeps Outperform Rating	MT

SpringWorks Therapeutics, Inc. Announces Resignation of Jeffrey Schwartz as Member of the Board and as Member of the Compensation Committee and the Audit Committee

September 01, 2023 at 04:01 pm EDT

On August 29, 2023, Jeffrey Schwartz informed the Board of Directors of SpringWorks Therapeutics, Inc. that he is resigning as a member of the Board and as a member of the compensation committee and the audit committee of the Board, effective immediately. Mr. Schwartz?s resignation is not the result of any dispute or disagreement with the Company.

Latest news about SpringWorks Therapeutics, Inc.

Transcript : SpringWorks Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 03:40 PM	May. 14
Wedbush Raises SpringWorks Therapeutics' Price Target to $75 From $70, Keeps Outperform Rating	May. 02	MT
SpringWorks Therapeutics Shares Fall After Wider-Than-Expected Q1 Loss	May. 02	MT
Transcript : SpringWorks Therapeutics, Inc., Q1 2024 Earnings Call, May 02, 2024	May. 02
Earnings Flash (SWTX) SPRINGWORKS THERAPEUTICS Reports Q1 Revenue $21M, vs. Street Est of $13.1M	May. 02	MT
SpringWorks Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
Transcript : SpringWorks Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 09:00 AM	Mar. 12
JPMorgan Adjusts Price Target on SpringWorks Therapeutics to $75 From $74, Keeps Overweight Rating	Mar. 06	MT
HC Wainwright Raises Price Target on SpringWorks Therapeutics to $74 From $73, Maintains Buy Rating	Mar. 06	MT
SpringWorks Therapeutics Starts Rolling New Drug Application for Prospective Tumor Treatment	Mar. 04	MT
SpringWorks Therapeutics, Inc. Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN	Mar. 04	CI
SpringWorks Therapeutics Q4 Net Loss Widens; Full-Year Net Loss Narrows	Feb. 27	MT
SpringWorks Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Earnings Flash (SWTX) SPRINGWORKS THERAPEUTICS Reports Q4 Revenue $5.4M	Feb. 27	MT
Wedbush Raises SpringWorks Therapeutics' PT to $70 From $60, Increases Sales Estimates for Ogsiveo, Mirdametinib; Keeps Outperform Rating	Feb. 26	MT
Wedbush Raises SpringWorks Therapeutics' PT to $60 From $45 on Increased Valuation for Ogsiveo in Desmoid Tumors; Keeps Outperform Rating	Feb. 07	MT
Springworks Therapeutics Insider Sold Shares Worth $1,160,362, According to a Recent SEC Filing	Feb. 06	MT
SpringWorks Therapeutics, Inc. Announces Resignation of L. Mary Smith as Chief Development Officer	Feb. 02	CI
Barclays Adjusts Price Target on SpringWorks to $47 From $41, Keeps Overweight Rating	Jan. 25	MT
Transcript : SpringWorks Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 07:30 AM	Jan. 08
SpringWorks Therapeutics Closes $316.3 Million Common Stock Public Offering	Dec. 08	MT
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday	Dec. 05	MT
Key Jobs Report Awaited as Exchange-Traded Funds, Equity Futures Decline Pre-Bell Tuesday	Dec. 05	MT
SpringWorks Therapeutics Prices $275 Million Share Offering	Dec. 05	MT
SpringWorks Therapeutics Launches $250 Million Public Offering of Shares; Stock Falls After Hours	Dec. 04	MT

Chart SpringWorks Therapeutics, Inc.

Duration

Period

More charts

Company Profile

SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer. OGSIVEO (nirogacestat) is the Company's Food and Drug Administration (FDA)-approved therapy. OGSIVEO (nirogacestat) is approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment. The Company also has a diversified targeted therapy pipeline spanning solid tumors and hematological cancers, with programs ranging from preclinical development through advanced clinical trials. Its ongoing developments include Nirogacestat for treatment of ovarian granulosa cell tumors, Nirogacestat in combination with B-cell maturation antigen (BCMA)-targeted agents, Mirdametinib Phase 2b ReNeu trial in NF1-PN and Brimarafenib (BGB-3245). The Company's early-stage pipeline includes SW-682, an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluated in Hippo-mutant solid tumors.

Sector

Biotechnology & Medical Research

Calendar

2024-05-31 - American Society of Clinical Oncology Annual Meeting - Abstract Number : 11520

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for SpringWorks Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

44.77 USD

Average target price

67.36 USD

Spread / Average Target

+50.46%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SPRINGWORKS THERAPEUTICS, INC.	+22.66%	3.31B
VERTEX PHARMACEUTICALS INCORPORATED	+8.29%	114B
REGENERON PHARMACEUTICALS, INC.	+10.21%	104B
BIONTECH SE	-11.90%	22.41B
ARGENX SE	+0.35%	22.28B
GENMAB A/S	-5.48%	19.07B
WUXI APPTEC CO., LTD.	-37.36%	18B
BEIGENE, LTD.	-5.17%	17.89B
NEUROCRINE BIOSCIENCES, INC.	+7.70%	14.28B
SAREPTA THERAPEUTICS, INC.	+37.65%	12.55B

Bio Therapeutic Drugs